A 3 months mild functional test regime does not affect disease parameters in young mdx mice

To assess the effect of potential therapeutic agents in dystrophic mice it is useful to have a functional test regime that does not affect the natural disease progression of mdx mice with dystrophinopathy. We determined the effect of a 12 week test regime consisting of fore limb grip strength, rotarod analysis and two and four limb hanging wire tests on the disease progression of 4-week-old mdx mice. Mice performed the different functional tests on consecutive days on a weekly basis. No difference was found in serum creatine kinase levels between functionally active and sedentary mice. The percentage of fibrotic/necrotic areas assessed in a semi-automated way with colour deconvolution of skeletal muscles, heart and diaphragm did not vary within muscles or between groups, nor did the gene expression levels of disease-related genes. We conclude that this test regime may be suitable for short-term functional evaluation of therapeutic approaches in the mdx mouse.

[1]  M. Ruegg,et al.  Mammalian animal models for Duchenne muscular dystrophy , 2009, Neuromuscular Disorders.

[2]  M. Grounds,et al.  Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment , 2008, Neuromuscular Disorders.

[3]  R. Abresch,et al.  Effect of voluntary wheel-running exercise on muscles of the mdx mouse , 1995, Neuromuscular Disorders.

[4]  A. De Luca,et al.  Enhanced Dystrophic Progression in mdx Mice by Exercise and Beneficial Effects of Taurine and Insulin-Like Growth Factor-1 , 2003, Journal of Pharmacology and Experimental Therapeutics.

[5]  A. Ruifrok,et al.  Comparison of Quantification of Histochemical Staining By Hue-Saturation-Intensity (HSI) Transformation and Color-Deconvolution , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[6]  P.A.C. ’t Hoen,et al.  T.P.1 03 Gene expression profiling to monitor therapeutic and adverse effects of antisense-induced exon skipping for Duchenne muscular dystrophy , 2006, Neuromuscular Disorders.

[7]  A. Hayes,et al.  Contractile function and low-intensity exercise effects of old dystrophic ( mdx) mice. , 1998, American journal of physiology. Cell physiology.

[8]  Bernard Dan,et al.  Pathophysiology of duchenne muscular dystrophy: current hypotheses. , 2007, Pediatric neurology.

[9]  T. Suga,et al.  Mdx respiratory impairment following fibrosis of the diaphragm , 2008, Neuromuscular Disorders.

[10]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[11]  G. S. Pandey,et al.  Preclinical drug trials in the mdx mouse: Assessment of reliable and sensitive outcome measures , 2009, Muscle & nerve.

[12]  Andrew P. Weir,et al.  Function and genetics of dystrophin and dystrophin-related proteins in muscle. , 2002, Physiological reviews.

[13]  J. Sanes,et al.  Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin α2-deficient mice , 2001, Neuromuscular Disorders.

[14]  K. Davies,et al.  The role of utrophin in the potential therapy of Duchenne muscular dystrophy , 2002, Neuromuscular Disorders.

[15]  J. Chamberlain,et al.  Dystrophin‐deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  E A Barnard,et al.  The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. , 1989, Science.

[17]  E. Hoffman,et al.  Dystrophin-deficient cardiomyopathy in mouse: Expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart , 2008, Neuromuscular Disorders.

[18]  J. Tremblay,et al.  Evidence of mdx mouse skeletal muscle fragility in vivo by eccentric running exercise , 1998, Muscle & nerve.

[19]  Eric P. Hoffman,et al.  Expression Profiling in the Muscular Dystrophies Identification of Novel Aspects of Molecular Pathophysiology , 2000 .

[20]  M. Grounds,et al.  Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy , 2008, Neurobiology of Disease.

[21]  B. Nico,et al.  Gentamicin treatment in exercised mdx mice: Identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle , 2008, Neurobiology of Disease.

[22]  M. S. Hudecki,et al.  Pre-clinical screening of drugs using the mdx mouse , 2000, Neuromuscular Disorders.

[23]  D. Allen,et al.  MUSCLE DAMAGE IN MDX (DYSTROPHIC) MICE: ROLE OF CALCIUM AND REACTIVE OXYGEN SPECIES , 2006, Clinical and experimental pharmacology & physiology.

[24]  L. Nolte,et al.  Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC‐1 , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  O. Halevy,et al.  Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone , 2008, Neuromuscular Disorders.

[26]  A. Connolly,et al.  Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout , 2007, Neuromuscular Disorders.

[27]  R. McCARTER,et al.  Voluntary exercise decreases progression of muscular dystrophy in diaphragm of mdx mice. , 1994, Journal of applied physiology.

[28]  I. Elmadfa,et al.  Decreased Mitochondrial Oxygen Consumption and Antioxidant Enzyme Activities in Skeletal Muscle of Dystrophic Mice after Low-Intensity Exercise , 2001, Annals of Nutrition and Metabolism.